25792 Improvements in BSA associate with improvements in itch and quality of life in patients with moderate-to-severe psoriasis treated with ixekizumab or guselkumab through 24 weeks

Abstract

Introduction/objective: Ixekizumab (IXE) and guselkumab (GUS) are approved to treat moderate-to-severe psoriasis in adults. We examined relationships of body surface area (BSA) involvement to itch and quality of life (QoL) following IXE and GUS treatment through 24 weeks.